Among the 17 patients with T2DM, eight (47.1%) were treated with antihypertensive agents, eight (47.1%) with hyperlipidemic agents, two (11.8%) with sulfonylurea, five (29.4%) with insulin, six (35.3%) with metformin, five (29.4%) with dipeptidyl peptidase 4 inhibitors, and two (11.8%) with sodium glucose cotransporter 2 inhibitors. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.